Ad5-GUCY2C-PADRE Colon Cancer Vaccine Effective in Humans

A phase I clinical trial reports that the cancer vaccine Ad5-GUCY2C-PADRE produces an immune response with minimal adverse events in patients with early-stage colorectal cancer. Colorectal cancer is the fourth most common cancer and the second leading cause of cancer death worldwide. Of the two-thirds of patients who undergo surgical resection with curative intent, 30% to 50% experience disease recurrence and die as a result of their cancer. Since adjuvant chemotherapy has no clinical benefit in...
Continue reading

New Cancer Vaccine Platform Enhances Therapeutic Efficacy

Researchers have developed a new cancer vaccine platform that enhances the efficacy of oncolytic viruses designed to activate the body's immune response against cancer cells. Cytotoxic T-cell lymphocytes (CTLs), otherwise known as CD8+ cells, specialize in killing damaged or infected cells, including those with cancer. These cells are essential to antitumor immunity, and the quantity of tumor-specific CTLs found in tumor tissue has been linked to patient survival. Oncolytic viruses—viruses desig...
Continue reading

Cancer Vaccine Attacks Multiple Targets for Better Results

In a strategy that may prevent tumors from eluding the immune system's attack, researchers have developed a new cancer vaccine capable of targeting multiple members of a cancer-causing family of proteins at once. Because proteins in the melanoma-associated antigen (MAGE-A) family are highly tumor specific and are overexpressed in several types of cancer, they have become a focus of recent immunotherapy research efforts. Yet melanoma and lung carcinoma investigations of MAGE-A3, a MAGE-A isoform ...
Continue reading

Experimental Cancer Vaccine Combination Is Effective Against Melanoma

Researchers have identified and optimized a synthetic chemical adjuvant that enhances an experimental cancer vaccine, enabling it to treat aggressive melanoma and immunize against its recurrence. For cancer immunotherapy to succeed, it must cause tumor antigen-specific cytotoxic T lymphocytes (CTLs) to activate, augmenting the body's own cancer-fighting ability. An adjuvant can strengthen this adaptive immune response, enhancing the body's attack on cancer antigens. Diprovocim, the adjuvant...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.